Overexpression of long noncoding RNA SLC26A4‐AS1 inhibits the epithelial–mesenchymal transition via the MAPK pathway in papillary thyroid carcinoma
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Cellular Physiology"
DOI: 10.1002/jcp.29145
Abstract: Papillary thyroid carcinoma (PTC) is recognized as one of the most prevalent types of thyroid cancer with poor prognosis. Long noncoding RNA (lncRNA) has undergone an intensive study for their involvement in tumor treatment. This… read more here.
Keywords: ptc; slc26a4 as1; as1; mapk pathway ... See more keywords
Overexpression of lncRNA SLC26A4‐AS1 inhibits papillary thyroid carcinoma progression through recruiting ETS1 to promote ITPR1‐mediated autophagy
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Cellular and Molecular Medicine"
DOI: 10.1111/jcmm.16545
Abstract: Papillary thyroid carcinoma (PTC), accounting for approximately 85% cases of thyroid cancer, is a common endocrine tumour with a relatively low mortality but an alarmingly high rate of recurrence or persistence. Long non‐coding RNAs (lncRNAs)… read more here.
Keywords: ptc; slc26a4 as1; progression; overexpression ... See more keywords
SLC26A4-AS1 Aggravates AngII-induced Cardiac Hypertrophy by Enhancing SLC26A4 Expression.
Sign Up to like & getrecommendations! Published in 2023 at "Arquivos brasileiros de cardiologia"
DOI: 10.36660/abc.20210933
Abstract: BACKGROUND It has been reported that solute carrier family 26 members 4 antisense RNA 1 (SLC26A4-AS1) is highly related to cardiac hypertrophy. OBJECTIVE This research aims to investigate the role and specific mechanism of SLC26A4-AS1… read more here.
Keywords: slc26a4 as1; angii induced; cardiac hypertrophy;